Healthcare Dive3h
Eli Lilly follows J&J in suing Biden administration over 340B rebates
Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Eli Lilly and Novo want to shake off Ozempic copycats. Are they ready to meet demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
Why Eli Lilly’s CEO says failing faster is essential to the company’s success
Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...
Smart toilet, AI platform among tech in use at drugmaker Eli Lilly’s new $42m hub in S’pore
The centre will improve the quality of medical research and explore new medicine. Read more at straitstimes.com.
The Motley Fool5d
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Nevertheless, the company's lead obesity candidate ... Adam Spatacco has positions in Eli Lilly. The Motley Fool has no ...
Verywell Health on MSN3d
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
STAT5h
Novartis ramps up in radiopharma, and Eli Lilly adds Zepbound details
In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...